This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bristol-Myers Squibb's CEO Discusses Q1 2012 Results - Earnings Call Transcript

We are glad about this European recognition of FORXIGA's benefit/risk profile for treating type 2 diabetes. And also, by the fact that the agency spoke specifically of the need for additional treatment options, while highlighting the significant unmet medical need in diabetes. We will work with the FDA to clarify a path forward in the U.S., and we continue the regulatory process in all other geographies.

Regarding ELIQUIS, we are looking forward to the FDA's upcoming decision on the atrial fibrillation indication, which will hopefully be followed by decisions in Europe and Japan where we have also filed. In partnership with Pfizer, our focus now is on implementing the most effective launch plan.

With respect to clinical developments, our pipeline remains robust and encouraging. As discussed at last week's EASL meeting, we are increasingly well positioned to meet the unmet medical need of the 170 million people worldwide who are chronically affected by hepatitis C. The data presented highlighted the broad portfolio of HCV assets that we have today, including a first-in-class NS5A inhibitor and demonstrated our diversified hepatitis C strategy based on multiple mechanism and combinations.

Thanks to the acquisition of Inhibitex and its potent nuc, we have broadened our portfolio of investigational HCV compounds and increased the potential opportunities to provide the right regimen for diverse patient populations. This is a high priority for our company, and we are devoting significant resources to it.

We are also making good progress with our immuno-oncology late stage pipeline, from our YERVOY development program, exploring additional indications in prostate and lung cancer, to our work with anti-PD-1 and other potential important asset entering Phase III for renal cell carcinoma, non-small cell lung cancer and melanoma. We plan to present data on anti-PD-1 at ASCO.

Read the rest of this transcript for free on seekingalpha.com

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs